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Data regarding the incidence, etiology and outcome of bloodstream infections taken on a broad European basis is scarce. 
We collected such information (ESGNI-001 and ESGNI-002 studies) and compared the situation in EU and non-EU 
European countries. 
A total of 122 hospitals from 28 countries participated in one or both studies. The global rate of blood cultures per 1,000 
admissions was 242.4, being significantly higher among EU countries (255.9) than in non-EU countries (192.8). Globally, 
14.4% of all blood extractions grew one or more microorganisms. The rate of positivity was significantly greater in non- 
EU countries (19.1%) than in EU countries (13.4%) (p<O.OOOI). The calculated incidence of significant episodes of 
bacteremia per 1,000 admissions was 27.2. 
The five most commonly isolated microorganisms were: Staphylococcus aureus, Escherichia coli, S. epidermidis and 
other coagulase-negative Staphylococci, S. pneumoniae and Pseudomonas aeruginosa. Overall, 11% of the episodes 
were polymicrobial (12.7% in EU countries versus 6% in non-EU countries; p=0.13). Gram-positive bacteria represented 
52.9% of all isolates, whereas Gram-negative bacteria were 41.2%. Fungi and anaerobes were 4.6% and 1.3% respec- 
tively. 
The acquisition of bloodstream infections was nosocomial in 72.8% of cases (68.3% in EU countries versus 86.5% in non- 
EU countries, p=0.003). 
According to the severity of underlying disease, 10.5% of the patients with significant bacteremia had rapidly fatal 
diseases, 38% had ultimately fatal diseases and 51% had diseases considered as non-fatal according to the McCabe 
classification. 
Regarding the severity score of sepsis, 76% were classified as plain sepsis, 14% as severe sepsis, 5.3% developed septic 
shock and 4.9% went on to have multiorganic failure. When EU and non-EU countries were compared there were no 
significant differences in the clinical data, reported between both groups. 
Overall, 22.6% of patients did not receive treatment or treatment was considered inadequate. The mortality rate was 
19.0% with a mortality attributable to bacteremia of 7.1%. Again, there were no differences between EU and non-EU 
countries. 
The multivariable analysis showed that the factors remaining independent predictors of mortality were: age (OR 
1.02-1.09; p=0.0002), severity of underlying diseases and severity of sepsis score. 
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INTRODUCTION 
Information regarding the evolution, incidence, etiology 
and prognosis of bloodstream infections is usually 
obtained from reports of single institutions in the ‘so- 
called’ developed world. These reports suggest an in- 
creasing trend in the incidence of significant bacteremia 
as well as a shift in the etiology of this dreaded infection 
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in recent years. This is probably related to changes in 
the underlying hseases of susceptible populations, to 
more aggressive and invasive medical practice, and to 
the presence of more virulent and difficult-to-treat 
microorganisms [l-91. 
Data regarding the incidence, etiology and out- 
come of bloodstream infections taken on a broad 
European basis is scarce, as is information concerning 
this issue in many countries not yet belonging to the 
European Union (EU). 
With these drawbacks in mind, the European 
Study Group on Nosocomial Infections (ESGNI) of 
the European Society of Clinical Microbiology and 
Infectious Diseases (ESCMID) undertook two comple- 
mentary studies (ESGNI-001 and ESGNI-002) designed 
to obtain information on the microbiology workload, 
prevalence, etiology and outcome of significant episodes 
ofbloodstream infections in EU and non-EU European 
countries. 
MATERIAL AND METHODS 
The ESGNI-001 study was a questionnaire directed to 
the microbiology laboratories of every European 
hospital with one or more ESCMID members and all 
those interested in participating from different Euro- 
pean hospitals, with the first part requesting information 
regarding the population served by the hospital, total 
number of beds, total number of admissions, total 
number of blood samples processed, total number of 
sterile samples and total number of positive samples 
(significant or not) during 1997. The second part of 
the ESGNI-001 questionnaire was a point prevalence 
study, collecting the information generated on a single 
day (March 25th, 1998) and requesting the following: 
total number of blood samples reported positive or 
negative that day, total number of samples with growth 
of one or more microorganisms either significant or 
contaminant, and total number of significant episodes 
of bloodstream infections reported on the study day. 
For each episode of significant bacteremia, we requested 
information regarding the microorganism or micro- 
organisms present and the antibiotic susceptibility profile, 
regardless of the laboratory method employed. The list 
of antimicrobials included: penicillin, ampicillin, 
ticarcillin, amoxicillin-clavulanate, methicillin, cefa- 
zolin, cefuroxime, cefotaxime, ceftazidime, imipenem, 
aztreonam, ciprofloxacin, cotrimoxazole, gentamicin, 
tobramycin, amikacin, streptomycin, rifampin, erythro- 
mycin, clindanlicin, vancomycin, tetracycline and chlor- 
amphenicol. 
ESGNI-002 was a clinical study related to ESGNI- 
001. We requested the following information from 
clinical microbiologists and clinicians regarding episodes 
of significant bacteremia occurring on the study day: 
age, sex, weighted index of comorbidity of the affected 
patient, classification of the underlying disease accord- 
ing to the McCabe and Jackson groups, severity of 
illness according to a sepsis score, and predisposing 
conditions for infection. With regard to antimicrobial 
treatment we classified it as adequate or inadequate, we 
registered days of antimicrobial administration and, 
finally patients were followed up until their death or 
discharge. Deaths were classified as attributable or not 
attributable to the bloodstream infection. 
Not all hospitals enrolled in ESGNI-001 were 
obliged to participate in ESGNI-002. This report 
brings together the information on the protocols 
received up to July 31st, 1998. 
Definitions used 
Sample: A sample is defined as a set of all blood culture 
bottles (aerobic and anaerobic) filled with a single blood 
extraction. 
Contaminant microorganism: The following micro- 
organisms are categorized as probable contaminants: 
Bacillus sp, Corynebacterium sp (except C. jeikeium), 
Lactobacillus sp, and Propionibacterium. Coagulase-negative 
Staphylococcus, or viridans group Sfreptococcus isolates, are 
considered to be probable pathogens only if they are 
recovered from two or more samples, or if the 
significance is clinically obvious. 
Polymicrobial bacteremia: polymicrobial bacteremia 
is defined as isolation of more than one microorganism 
during a single bacteremic episode. 
Bloodstream infectious episode: Episodes of 
bacteremia, fungemia, or mycobacteremia refer only to 
patients. All microorganisms isolated from blood within 
one week are considered as a single episode. 
Nosocomial bloodstream infection: a nosocomial 
episode is considered to be the occurrence of any 
bloodstream infection beginning at least 72 hours after 
admission. The same definition is applied to fungemia. 
Severity of illness [lo]: 
Sepsis: Systemic response manifested by two or more 
of the following conditions as a result of infection: 
(a) temperature >38"C or <36"C; (b) heart rate 
> 90 beats/min; (c) respiratory rate > 20 breaths/ 
min or PaCOz <32 mmHg; (d) WBC >12,000 
cells/mm3, <4,000 cells/mm', or >lo% immature 
(band) forms. 
Severe sepsis: Sepsis associated with organ dysfunc- 
tion, hypoperfiision or hypotension. Hypoperfusion 
and perfusion abnormalities may include, but are 
not limited to, lactic acidosis, oliguria or an acute 
alteration in mental status. 
Septic shock: Sepsis with hypotension, despite ade- 
quate fluid resuscitation, along with the presence of 
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perfusion abnormalities that may include, but are 
not limited to, lactic acidosis, oliguria or an acute 
alteration in mental status. Patients who are on 
inotropic or vasopressor agents may not be hypo- 
tensive at the time that perfusion abnormalities are 
measured. 
Multiorganfailure: Failure of three or more organ 
systenis during at least a 24-hour period, as a 
consequence of bacteremia. 
Predisposing factors to bloodstream infection: 
(a) Bladder catheter, intravenous catheter, intubation, 
neutropenia and prosthetic material if they were present 
at  the time of infection; (b) surgery if it was during 
hospital admittance; (c) corticosteroids if they have 
been taken a t  a dose of 20 mg of prednisone daily (or 
equivalent) for at least two weeks, or 30 mg of 
prednisone daily for at least one week, before the 
positive blood culture; (d) cytotoxic therapy if the 
patient received any kind of antineoplasic in the four 
weeks previous to the bloodstream infectious episode; 
(e) antibiotics if the patient received any oral or 
parented antibiotic in the 15 days previous to the 
bloodstream infectious episode; (0 upper/lower endo- 
scopy and urological intervention if they were 
performed in the 72 hours previous to the bloodstream 
infectious episode; and (g) other invasive procedures 
(i.e. deep tissue biopsy, bronchoscopy, cardiac catheteri- 
zation, etc.) if they were performed in the 72 hours 
previous to the bloodstream infectious episode. 
Adequacy of treatment: Treatment is considered 
adequate if the patient received one or more antibiotics 
active in vitro against the microorganisms isolated, for 
at least seven days. 
Days of treatment: Consider only the number of days 
of adequate treatment. 
Death attributable to bloodstream infection: 
Death is considered as attributable to bloodstream in- 
fection if it occurs during the phase of active infection 
or while the patient is undergoing antibiotic treatment. 
The McCabe and Jackson groups [ l l ] ,  and the 
Charlson weighted index [12] were used as co- 
morbidity indexes. 
Data analysis 
We expressed continuous variables as the mean and 
standard deviation (SD) when normally distributed or 
as the median and interquartile range (IQR) if their 
distribution was skewed, and discrete variables as 
percentages. We used the Student’s unpaired t-test to 
compare continuous variables, the Mann-Whitney U- 
test to compare continuous variables not normally dlstri- 
buted, and the chi-square or Fisher exact test to compare 
proportions. AU statistical tests were two-tailed. 
To control for confcunding variables in the analysis 
of death among patients with bacteremia, we carried 
out a multivariable analysis by logistic regression (LR) 
that gave us a mathematical model relating the death to 
the different risk factors. We performed the L R  with 
the enter method, and the inclusion of variables in the 
model was decided according to their significance in 
the bivariable analysis, together with the importance 
given to each variable regardless of whether or not it 
was clearly significant in this analysis. The model was 
adjusted using the Hosmer-Lemeshow method. We 
calculated the odds ratio and 95% CIS for all significant 
predictors of death. The final model included the 
following variables: severity of illness, McCabe and 
Jackson groups, days of treatment, age, Charlson index, 
adequacy of treatment and the presence of bladder 
catheter, intubation, treatment with corticosteroids or 
previous use of antibiotics. We also tested for all 
painvise interactions between significant risk factors in 
the multivariable model. 
A total of 122 hospitals from 28 countries participated 
in one or both studies (Table 1). Although most of 
Table 1 Participant hospitals 
Count1y No of hospitals participating 
Austria 
Belgium 
Bulgaria 
Croatia 
Czech Republic 
Denmark 
Finland 
France 
Germany 
Greece 
Holland 
Hungary 
Iceland 
Ireland 
Italy 
Latvia 
Lithuania 
Norway 
Portugal 
Russia 
Slovak Republic 
Slovenia 
Spain 
Sweden 
Switzerland 
Turkey 
United Kingdom 
Yugoslavia 
6 
6 
2 
6 
5 
1 
1 
9 
8 
1 0 
7 
2 
1 
1 
9 
1 
1 
3 
4 
1 
2 
2 
16 
2 
3 
4 
8 
1 
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Table 2 Microbiology workload in 1997 
EU countries Non-EU countries Total 
(n =84) (n =28) (n =112) 
Total number of blood samples 704,843 143,963 848,806 
Total number of admissions 2,753,600 746,730 3,500,330 
Admissions/blood sample 3.9 5.1 4.12 
Blood samples/1,000 ad. Year* 255.9 192.8 242.4 
Positive blood samples 94,831 27,595 122,426 
Percentage of positives * 13.4% 19.1% 14.4% 
*p<0.001. 
those participating sent both studies, this was not so in 
every case. Therefore, the tables indicate on which basis 
(hospitals or cases) the calculations have been made. 
Laboratory workload of bloodstream infections during 1997 
We obtained this information from 112 hospitals of 
different size (26.7% had up to 500 beds, 34.2% had 
501-1000 beds, and 39.1% more than 1000 beds). 
Overall, the total number of admissions in those 
institutions during 1997 was 3,500,330 and the total 
number of blood samples obtained for blood culture 
was 848,806 (Table 2). This means a blood sample for 
blood culturing every 4.12 admissions. The global rate 
ofblood cultures per 1,000 admissions was 242.4, being 
significantly higher among EU countries (255.9) than 
in non-EU countries (192.8). Globally, 14.4% of all 
blood extractions grew one or more microorganisms. 
The rate of positivity was significantly greater in non- 
EU countries (19.1%) than in EU countries (13.4%) 
(p < 0.0001). 
Microbiology data on the study day 
Data regarding microbiology workload on the study 
day is largely confirmatory of 1997 data. We recorded 
3183 blood samples taken for culture in 112 in- 
stitutions, of which 496 were positive (15.5%), repre- 
senting 261 episodes of significant bacteremias (Table 
3). 
Table 3 Data regarding the study day (25th March, 1998) 
EU Non-EU 
countries countries Total 
(n=84) (n=28) (n=112) 
Total number of 
Positive blood samples 396 100 496 
Significant episodes of 
bloodstream infection 200 61 261 
Percentage of positives* 15% 18.4% 15.5% 
blood samples 2,639 544 3,183 
If we take the total number of admissions in 1997 
(Table 1) we can make a rough estimate of the rate of 
significant bacteremic episodes per 1000 admissions. 
The total number of significant bacteremic episodes on 
the study day was 261 (Table 3), and the daily number 
of admissions can be estimated as 3,500,330/365 days 
= 9590 admissions per day. Therefore, the incidence 
of significant episodes of bacteremia per 1000 admis- 
sions would be 27.2. 
The number of microorganisms isolated from 
significant episodes of bacteremia was 304. The 
etiology of the episodes is summarized in Table 4. The 
five most commonly isolated microorganisms were: 
S. aureus, E. coli, S. epidermidis and other coagulase- 
negative Staphylococci, S. pneumoniae, and l? aeruginosa. 
Overall, 11% of the episodes were polymicrobial 
(12.7% in EU countries versus 6% in non-EU 
countries; p =0.13). Gram-positive bacteria repre- 
sented 52.9% of all isolates, whereas Gram-negative 
bacteria were 41.2%. Fungi and anaerobes were 4.6% 
and 1.3% respectively. The type of microorganism was 
comparable between both groups of hospitals (EU and 
non-EU) with the single exception of Aeudomonas 
Table 4 Most frequent isolates 
EU Non-EU 
countries countries Total 
(n =233) (n=71) (n=304) 
S. uureus 37 9 46 (15.1%) 
E. coli 37 7 44 (14.5%) 
S. epidermidis 21 12 33 (10.8%) 
CNS 14 7 21 (7.0%) 
S. pneumoniue 16 7 18 (5.9%) 
l? uenrginosu* 7 9 16 (5.3%) 
K.  pneumoniue 11 5 16 (5.3%) 
Cundida spp 10 4 14 (4.6%) 
Enterococcus spp 11 3 14 (4.6%) 
Acinetobacter spp 7 4 11 (3.6%) 
Other 51 7 59 (19.4%) 
(C. albicans) (4) (3) 7 (2.3%) 
Enterobucter spp 10 7 12 (3.9%) 
*p=0.048. *p=0.03 
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aeruginosa which was isolated more frequently in non- 
EU countries ( p  =0.03). 
The acquisition of bloodstream infections was 
nosocomial in 72.8% of the cases (68.3% in EU coun- 
tries versus 86.5% in non-EU countries, p =0.003). 
Resistance patterns of the most frequent isolates 
The ESGNI-001 study was not designed to study the 
prevalence of antibiotic resistance among the different 
organisms obtained from bloodstream infections, given 
the small number of isolates that can be collected in a 
single day and because sensitivity assays were not 
performed in a central laboratory. Despite this, we 
considered the information summarized in Table 5 of 
interest. Overall, 43% of S. aureus were resistant to 
methicillin and no isolate was resistant to vancomycin. 
The percentage of E. coli resistant to ampicillin was 
52%. Macrolide-resistant S. pneumoniae occurred in 
31.5% of the isolates and imipenem- resistant I? 
aeruginosa occurred in 25% of the isolates. 
Clinical information 
We obtained complete clinical information of the 
protocol in 228 individuals with bloodstream infections 
active on the study day (Table 6). There were 113 males 
(52%) and 105 females (48%) whose ages ranged from 
less than 1 year to 96 years (mean 49 years, SD 25.7). 
According to the severity of underlying disease, 
10.5% of the patients had rapidly fatal diseases, 38% had 
Table 5 
ultimately fatal diseases and 51% had diseases con- 
sidered as non-fatal according to the McCabe and 
Jackson classification. Comorbidity illnesses were rated 
according to Charlson’s criteria and the mean index was 
2.97 (range 0-13). 
Regarding the severity score of sepsis, 76% were 
classified as sepsis, 14% as severe sepsis, 5.3% developed 
septic shock and 4.9% went on to have multiorganic 
failure. 
The most important predisposing factors for 
bacteremia are summarized in Table 7. Overall, intra- 
venous catheter, previous antibiotic use, urinary catheter 
and previous surgery were the most common (Table 7). 
When E U  and non-EU countries were compared, 
there were no significant differences in the clinical data 
between both groups. 
Overall, 92.9% of patients received antibiotic 
treatment, considered as adequate in 77.4%) of all 
patients (175/226). Therefore 22.6% ofpatients did not 
receive treatment, or treatment was considered in- 
adequate. The median of days of treatment was 10 
(IQR 5-14d; range 0-50). The mortality rate was 
19.0% with a mortality attributable to bacteremia of 
7.1% (Table 8). Again, there were no differences 
between EU and non-EU countries. 
Clinical characteristics and predisposing factors for 
infection were compared in patients who died and who 
survived (Table 9). In the univariate analysis, overall 
mortality was associated with advanced age, poor state 
Microorganism Antimicrobial Total N o  of isolates tested 96 of resistance 
S. aureus Methicillin 42 42.8 
S. aureus Ciprofloxacin 28 39.3 
S. aureus 
S. aureus 
E.  toli 
E.  coli 
E.  coli 
E. coli 
S. epidermidis and other CNS 
S. epidrrinidis and other CNS 
S. pneuvnottiae 
S. pneumoniae 
S. prieumoriiae 
I? aeruginosa 
J? aerqiuosa 
I? aerugiriosa 
I? aeruxinosa 
K. pneumoniae 
K .  pneumoniae 
K. pneumoniae 
Enterococcus spp 
Enterococcus spp 
Cotrimoxazole 
Vancomycin 
Ampicillin 
Amoxicillin-clavulanate 
Ciprofloxacin 
Cotrimoxazole 
Methicillin 
Vancomycin 
Penicillin 
Vancomycin 
Erithromycin 
Ceftazidime 
Imipenem 
Ciprofloxacin 
Gentamicin 
Cefotaxime 
Imipenem 
Ciprofloxacin 
Ampicillin 
Vancomycin 
35 
45 
42 
33 
42 
35 
46 
49 
16 
13 
16 
15 
16 
15 
13 
16 
16 
15 
10 
9 
8.6 
0.0 
52.3 
12.1 
9.5 
22.8 
63.0 
0.0 
0.0 
0.0 
31.5 
26.7 
25.0 
13.3 
23.0 
31.2 
0.0 
0.0 
10.0 
0.0 
There were no statistical differences between EU and non-EU countries according to the percentage of resistance, with the exception of 
K. pneumoniae (resistance to cefotaxime was observed only in non-EU countries). 
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Table 6 Demographic and clinical data 
EU countries Non-EU countries Total 
(n=168) (n =60) (n=228) 
Age (SD) range 50.9 (25.9) G 9 6  45.5 (24.6) 0-79 49.0 (25.7) 0-96 
Sex: Female 81 (48.2%) 24 (40%) 105 (48.2%) 
Male 87 (51.8%) 36 (60%) 113 (51.8%) 
Charlson index (SD) range 2.98 (2.6) 0-13 2.93 (3.0) 0-13 2.97 (2.7) G 1 3  
Mc Cabe and Jackson groups: 
1 15 (8.9%) 9 (15%) 24 (10.5%) 
2 64 (38.1%) 23 (38.3%) 87 (38.1%) 
3 89 (53.0%) 28 (46.7%) 117 (51.4%) 
Sepsis 126 (76.8%) 45 (72.7%) 171 (75.7%) 
Severe sepsis 23 (14.0%) 9 (14.5%) 32 (14.1%) 
Severity of illness*: 
Septic shock 7 (4.3%) 5 (8.0%) 12 (5.3%) 
Multiorgan failure 8 (4.9%) 3 (4.8%) 11 (4.9%) 
*n=226. 
Table 7 Predisposing factors to bloodstream infection 
EU countries 
(n=168) 
Nan-EU countries 
(60) 
Total 
(228) 
IV catheter 
Previous use of antibiotics 
Bladder catheter 
Previous surgery 
Intubation 
Corticosteroids 
Cytotoxic therapy 
Prosthetic material 
Other invasive procedures 
Neutropenia 
Upper/lower endoscopy 
Urological intervention 
HIV infection 
123 (73.2%) 
95 (56.5%) 
64 (38.1%) 
44 (26.2%) 
45 (26.8%) 
33 (19.6%) 
22 (13.1%) 
18 (10.7%) 
19 (11.3%) 
15 (8.9%) 
7 (4.2%) 
3 (1.8%) 
14 (8.3%) 
39 (65.0%) 
39 (65.0%) 
17 (28.3%) 
10 (16.6%) 
14 (23.0%) 
14 (23.0%) 
6 (10.0%) 
5 (8.3%) 
9 (15.0%) 
5 (8.3%) 
20 (33.3%) 
2 (3.3%) 
0 (0.0%) 
162 (71.0%) 
134 (58.8%) 
84 (36.8%) 
61 (26.7%) 
55 (24.1%) 
47 (20.6%) 
36 (15.8%) 
24 (10.5%) 
24 (10.5%) 
23 (10.0%) 
20 (8.8%) 
3 (1.3%) 
9 (3.9%) 
Table 8 Antibiotic treatment and outcome 
EU countries Non-EU countries Total 
(n=226) 
Treatment given 151 (90.4%) 58 (98.3%) 209 (92.5%) 
175 (77.4%) Treatment adequate 129 (77.2%) 46 (78.0%) 
Patient death 29 (17.4%) 14 (23.7%) 43 (19.0%) 
Death attributable to bloodstream infection 12 (7.2%) 4 (6.8%) 16 (7.1%) 
(n=167) (n=59) 
Median days of treatment (IQR), range 9 d (5-14), 0-50. 10 d (5-14), G 3 5  10 d (5-14). 0-50 
of health prior to the bacteremic episode and a age (OR 1.02-1.09; p=0.0002), severity ofunderlying 
higher severity of illness, a shorter number of days of diseases and severity of sepsis score (Table 10). While 
treatment, the presence of indwelling catheterization, the severity of dness score was predictive overall and 
tracheal intubation and inadequacy of antimicrobial for each category, the McCabe and Jackson groups 
therapy. were good overall but only the rapidly fatal category 
The multivariable analysis showed that the factors showed significantly more risk of death. 
remaining independent predictors of mortality were: 
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Table 9 Comparison between patients according to outcome 
Patients who survived Patient who died 
(n=183) ( n  =43) P value 
Age (SD) 45.4 (26.4) 63.8 (15.9) <0.001 
Sex (male) 94 (51.4%) 28 (65.1%) NS 
Charlson index (SD) 2.82 (2.7) 3.67 (2.87) 0.046 
McCabe and Jackson <0.001 for linear trend 
Non-fatal 106 (57.9%) 1 0  (23.3%) 
Ultiinately fatal 68 (37.2%) 18 (41.9%) 
Rapidly fatal 9 (4.9%) 15 (34.9%) 
Severity <0.001 for linear trend 
Sepsis 154 (84.1%) 17 (39.5%) 
Severe sepsis 22 (12.0%) 10 (23.3%) 
Septic shock 5 (2.7%) 7 (16.3%) 
Multiorgan failure 2 (1.1%) 9 (20.9%) 
Treatment days (SD) 10.03 (8.3) 6.1 (9.2) 0.008 
Bladder catheter 57 (31.1%) 27 (62.8%) <0.001 
lntubation 36 (19.7%) 19 (44.2%) 0.001 
Corticosteroids 33 (18.0%) 14 (32.6%) 0.058 
IV catheter 130 (71.0%) 32 (74.4%)) NS 
Previous use of antibiotics 103 (56.3%) 31 (72.1%) 0.060 
Previous surgery 49 (27.2%) 12 (28.6%) NS 
Cytotoxic therapy 29 (15.8%) 6 (14.0%) NS 
Prosthetic material 20 (10.9%) 4 (9.3%) NS 
Other invasive procedures 18 (9.8%) 6 (14.0%) NS 
Neutropenia 19 (10.4%) 4 (9.3%) NS 
Upper/lower endoscopy 16 (8.7%) 4 (9.3%) NS 
Urological intervention 5 (2.7%) 4 (9.3%) NS 
HlV infection 3 (1.6%) 0 (0%) NS 
inadequate treatment 36 (19.7%) 15 (34.9%) 0.041 
Table 10 Risk factors for mortality among patients with 
bacterenua 
Odds ratio OK 95% CI P value 
Severity 
Sepsis 1 Keference category 
Severe sepsis 6.50 1.83-23.05 0.0037 
Septic shock 12.02 2.58-55.98 0.0015 
Multiorgan failure 99.43 8.75-1 129.26 0.0002 
McCabe and Jackson 0.0004 
Ultiinately fatal 1.77 0.57-5.47 0.31 
Rapidly fatal 24.82 4.Y1-125.31 0 .000 1 
Age (fbr each year) 1.05 1.02-1.09 0.0002 
Non-fatal 1 Reference category 
DISCUSSION 
There is general agreement on drawing blood for 
culture in febrile (938°C) or hypothermic patients, in 
patients with leukocytosis (2 10,000 wbc/pL), in those 
with granulocytopenia (< 1,000 g/pL) and in neonates 
and elderly patients who may remain afebrile despite 
other signs of sepsis [13]. However, we were unable to 
find reliable figures regarding the number of blood 
cultures considered adequate or inadequate in the 
microbiology laboratory workload of modern insti- 
tutions. In this study, the number of blood samples per 
1000 admissions was 242.4 with a percentage of 
positive samples of 14.4%. The rate is higher in EU 
countries when compared with non-EU countries, 
although the rate ofpositivity is higher in the last group, 
in comparison with E U  countries. This fact may reflect 
a lesser use of blood cultures which would normally 
be carried out on people with a higher suspicion of 
bacteremia in non-EU countries. 
Our  data provide a figure of 27.2 episodes of 
significant bacteremia per 1000 admissions with no 
statistically significant differences between EU and 
non-EU countries. This is in the rank of other reports 
published previously [1,3,14-16]. 
O n  a pan-European basis this study confirms the 
shift in the etiologic spectruni of bacteremia observed 
in recent years in diKerent institutions [4,6,9,17]. 
Gram-positives represented 52.9% of all isolates, 
while Gram-negatives, fungi and anaerobes represented 
41.296, 4.6% and 1.396, respectively. The most frequent 
microorganism isolated was S. aureus (lS.196) but 
Staphylococcus coagulase-negative (CNS) and S. epider- 
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midis both constitute 17.8% of all isolates. This number 
of Gram-positives can be explained by the appearance 
of new mechanisms of resistance in some cases, better 
control and treatment of Gram-negatives, and the 
appearance of population groups susceptible to this 
type of infection, such as IVDU, patients with 
prosthetic material and patients with indwelling 
intravenous catheters [4,17-201. 
Gram-negatives represented the second biggest 
group of isolates, E. coli being the second most frequent 
microorganism overall (14.5%), followed by l? aerugiiiosa 
and Klebsiella pneumoniae. These results are in agree- 
ment with other studies previously published [6,21-231. 
Regarding fungemia, Candida is the etiologic agent 
in the vast majority of episodes. In recent years, an 
increasing trend in the incidence of episodes of 
candidemia has been reported 124-321. It amounted to 
8% of all episodes of significant bloodstream infections 
in the SCOPE Program in the USA 1321. At the same 
time, many institutions reported a shift to non-albicans 
species which now represent at least 50% of the isolates 
in many reports [24-26,291. In our study, 4.6% of 
overall isolates belonged to the genus Candida,  but only 
7 out of 14 were C. albicans. This may be partly due to 
the more widespread use of antifungal drugs, especially 
imidazols, not only as treatment but also as prophy- 
laxis. 
During the last decade there has been a progressive 
decline in the incidence of anaerobic bacteremias. 
At present, anaerobes represent less than 5% of all 
documented bloodstream infections [4,33-351 and the 
systematic convenience of an anaerobic bottle in all sets 
of blood cultures has been questioned. Our study also 
shows a very low percentage (1.3%) of anaerobic blood- 
stream infections in Europe. 
The incidence of polymicrobial bacteremia has also 
been increasing in recent decades with a frequency 
which varies between 5 and 22% of all bacteremias 
[3,36-381. The information collected in our study is 
comparable to that already reported showing a figure of 
11% with no significant differences between EU and 
non-EU countries. 
The ESGNI-001 study was not designed to study 
in detail the prevalence of antibiotic resistance among 
the different organisms obtained from bloodstream 
infections, due to the limited number of isolates 
obtained and the absence of a uniform methodology in 
the antimicrobial resistance assays. Nevertheless, some 
data deserve special attention. Methicillin resistance 
appears widespread and high among S. aureus (42.8%), 
S. epidevmidis and other CNS (63.0%) collected in our 
study. Prior European data are scarce and show a wide 
variation of MRSA among countries and institutions 
in Europe [39-441. 
The number of isolates in other microorganisms 
does not permit any firm conclusion regarding 
antimicrobial resistance. Several studies have tried to 
assess the issue of European antimicrobial resistance in 
different microorganisms in recent years 139-491. 
Clinical data obtained in this study showed an un- 
surprising age and sex distribution of patients with 
bloodstream infections. Bacteremia can occur in 
patients of any age group, but the classic pattern 
involves two large peaks of incidence. One represents 
bacteremia during the first years of life and the other 
usually appears from the age of 50. Neither demo- 
graphic characteristics nor predisposing factors to 
developing bacteremia were different in EU and non- 
EU countries. The most frequently observed pre- 
disposing factors in our study implied the rupture of 
natural barriers: intravenous catheter, bladder catheter, 
surgery and intubation. The second largest group 
involved factors that impaired the general mechanisms 
of defense such as the use of corticosteroids, cytotoxic 
therapy or neutropenia. To our surprise, only 1.3% of 
all episodes detected in a single day occurred in HIV- 
positive patients. 
The acquisition of bloodstream infections is also 
shifting from a predominantly nosocomial origin to an 
increasingly frequent community acquisition [ 1,3,6]. 
This is probably due to shorter periods of hospital stay 
even in severely ill patients. The pan-European data of 
73% nosocomial-acquisition show sipficant differences 
between EU (68% nosocomial) and non-EU countries 
(86.5% nosocomial; p =0.003). 
There is a not unquestionably established duration 
of treatment for bloodstream infections which usually 
varies from 5 to 14 days. Our data show 10 days as the 
median period of therapy in European hospitals. Our 
data also show a more striking feature regarding 
therapy. Overall, almost 23% of our patients did not live 
long enough to receive adequate treatment or were 
treated with inadequate antimicrobial agents. This is 
clearly a variable for intervention. It is a responsibility 
of clinical microbiologists to delineate better procedures 
for conveying rapidly to the bedside information regard- 
ing etiology and antimicrobial susceptibility patterns of 
isolates from bloodstream infections [50,51]. 
The death of a patient with bacteremia is not 
infrequent and occurs in up to 45% of cases [1,3,14,52, 
531. The apparent discrepancy in the figures is due 
to the populations selected in the studies. The lowest 
rates are observed in gyne-obstetric patients, who 
are generally younger and have no underlying ill- 
ness and a better prognosis 152,541. At the other 
extreme we can find patients admitted to the intensive 
care unit or patients with a serious underlying disease 
114,551. 
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In our study, overall mortality was 19% whereas 
death attributable to bacteremia was 7.1% with no 
differences observed between both groups of countries. 
Mortality was independently associated with advanced 
age, poor state of health prior to the bacteremic 
episode and a higher severity of illness. Regarding this 
last issue, risk for mortality was 6.5, 12.02 and 99.43 
times higher for patients with severe sepsis, septic 
shock and multiorgan failure, respectively, compared to 
patients with sepsis only. Furthermore, when we 
studied the mortality rate for each category, we noticed 
that patients with sepsis presented 10.4% mortality and 
this proportion increased with severity: severe sepsis 
31.2%, septic shock 58.3% and multiorgan failure 
81 3%. This correlation between progressively more 
severe situations and growing mortality has also been 
well documented elsewhere [55,56]. 
O n  the other hand, in cases where antibiotic 
treatment was considered inadequate in the terms 
defined in the protocol, mortality was significantly 
higher than when it was considered adequate (29.4% 
versus 26.7%; p=0.041). This may reflect not only 
inappropriate antibiotic treatment, but also a situation 
where patients did not survive long enough to receive 
a complete course of antibiotic treatment. In this 
way, adequacy of treatment was not an independent 
predictor of mortality, maybe because it was related to 
more severely ill patients rather than being the optimal 
treatment. This was corrected in the L R  model 
according to severity. 
O n  a broad European basis, our survey shows the 
situation of bloodstream infections in Europe, their 
laboratory workload, shift in etiology and significant 
morbidity and mortality, which leave clear spaces for 
future intervention. 
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